Stakeholder opinions on value in healthcare

Abstract

ObjectivesTo determine how the value of new medicines is defined from the perspective of different stakeholders in nine European countries.MethodsWe carried out an explorative survey by conducting in-depth qualitative interviews with a range of experts with health technology assessment, clinical provision, health economics, payer, academic and industry experience. Experts were asked to distribute 100 points over a predefined list of attributes related to value. In total, 30 interviews were conducted with seven academics, five clinicians, nine economists, five payers and four providers. Each of these categories was represented in responses from France, Germany, the Netherlands and the UK.ResultsComments on the interview guide were all positive. There was substantial variation in definitions of value provided by respondents. Most respondents indicated that delivering benefits to the patient is a prerequisite for a healthcare product to be of value, but only half included costs or resource use in their definition. Quantitative responses showed that effectiveness and efficacy were considered the most important attributes of value, followed by safety and side effects. Lower scores were given to other attributes, such as dignity and individualism, and invasiveness of the treatment. Resources and costs associated with complications and readmissions were considered important by academics and economists, but not clinicians.ConclusionsThe interview findings indicate that the value of a drug is subjective in being perceived differently by different stakeholders, and for different treatment types. Future research will require evaluation of the views of a larger number of stakeholders in more and different countries to confirm these findings.

Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment

“…Similarly, opinions from multiple stakeholders should also be considered during drug value assessments. [52] Among these, the patients’ voice and the opinion of the patient group should be given more consideration than is typically the case. [53] Based on the research results, regardless of whether or not the opinions of the patient group or the industry on weights were considered, the final research results remained unaffected.…”

Multi-Criteria Decision Analysis as a Decision-Support Tool for Drug Evaluation: A Pilot Study in a Pharmacy and Therapeutics Committee Setting

“…This pilot study had some limitations mainly due to the inherent nature of the study focused only in a P&TC setting. Recent studies have suggested that, in healthcare decision making, the stakeholders would give different values to different criteria and that values assigned in drug evaluation are subjective and depending on their objectives and their points of view (24). In this context, it has been reported that when evaluating the contribution of a new medical device the relative importance of the criteria framework was in accordance with points of view of evaluators and their objectives (25).…”

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

“…The impact of the therapy on life expectancy and quality of life, the cost of the new therapy, and the burden on the system of integrating a new drug are among the factors that are considered when a government decides if it will pay for a new therapy [71]. Stakeholders differ in their perspectives of what constitutes value [72][73][74][75]. Patients, their loved ones, and their physicians want access to therapies that improve cancer symptoms, prolong life, and offer hope.…”